Tag: IMGN779
Amid Significant Progress, Robust Growth and Advancing Pipeline — Immunogen Closes...
A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company's...
Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...
This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...
Jazz Pharmaceuticals and ImmunoGen Sign Development and Commercialization Agreement
Jazz Pharmaceuticals, an international biopharmaceutical company focusing on address unmet medical needs and ImmunoGen, a clinical-stage biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate...
IMGN779 Demonstrates Favorable Safety Profile with repeat Dosing and no Dose-limiting...
The first-in-human data demonstrate the safety and tolerability of IMGN779, being developed by ImmunoGen, across seven dose levels, with no dose limiting toxicities (DLTs),...
IMGN632, a Novel CD123-Targeting Antibody-drug Conjugate, Demonstrates Activity in Acute Myeloid...
Preclinical data on IMGN632, a novel CD123-targeting antibody-drug conjugate being developed by ImmunoGen, presented at the 58th American Society of Hematology (ASH) Annual Meeting...
ASH 2016: Informative and Clinical Useful
Each year, ahead of key annual medical society meetings we ask the same question: What to expect during the upcoming meeting. Are we going...
IMGN779 Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML...
CD33 is broadly expressed on leukemic blasts of patients with acute myeloid leukemia. Although nearly 80% of patients show a high initial response rates to chemotherapy, many...
Preclinical Data of Novel Antibody-drug Conjugate IMGN779 Demonstrates Potent Activity Against...
Results from a preclinical trial shows that IMGN779, a novel, DNA-alkylating, anticancer therapeutics based on ImmunoGen, Inc, antibody-drug conjugates (ADC) technology, shows potent activity against CD33-expressing acute myeloid leukemia cells,including leukemic stem cells, while sparing normal cells.
